Takeda Kept Generic Drug Off Shelves For 6 Years, Suit Says

By Chris Villani (August 3, 2021, 11:34 AM EDT) -- Takeda Pharmaceutical Co. Ltd. was hit with a proposed class action Tuesday in Massachusetts federal court by a drug company who claims the pharmaceutical giant paid a competitor to keep a generic anti-constipation drug off the market for six years to preserve Takeda's monopoly.

According to the complaint, Takeda paid Par Pharmaceutical Inc. in late 2014, so the latter company would not go to market with generic Amitiza. The deal kept Takeda as the only game in town for a drug with lubiprostone as the active pharmaceutical ingredient, the suit claims, and Takeda shared the monopoly's profits with Par, which is...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!